[{"id":"c5926a3c-11fc-4d8b-a13e-2af41702c630","acronym":"","url":"https://clinicaltrials.gov/study/NCT03866382","created_at":"2021-01-18T19:04:09.999Z","updated_at":"2025-02-25T12:37:16.517Z","phase":"Phase 2","brief_title":"Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors","source_id_and_acronym":"NCT03866382","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • CD4","pipe":"","alterations":" ","tags":["PD-L1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • cisplatin • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 314","initiation":"Initiation: 05/13/2019","start_date":" 05/13/2019","primary_txt":" Primary completion: 02/28/2026","primary_completion_date":" 02/28/2026","study_txt":" Completion: 02/28/2026","study_completion_date":" 02/28/2026","last_update_posted":"2025-02-24"},{"id":"cd9c94c5-ad9b-4ee8-a453-d749f2f2d4c8","acronym":"","url":"https://clinicaltrials.gov/study/NCT05111574","created_at":"2021-11-08T14:53:11.866Z","updated_at":"2025-02-25T12:38:02.656Z","phase":"Phase 2","brief_title":"Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery","source_id_and_acronym":"NCT05111574","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • ABP 206 (nivolumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 99","initiation":"Initiation: 08/11/2022","start_date":" 08/11/2022","primary_txt":" Primary completion: 12/19/2025","primary_completion_date":" 12/19/2025","study_txt":" Completion: 12/19/2025","study_completion_date":" 12/19/2025","last_update_posted":"2025-02-24"},{"id":"9c0791f2-df06-44ae-99f3-11a3ceff187a","acronym":"","url":"https://clinicaltrials.gov/study/NCT02496208","created_at":"2021-01-18T12:02:15.721Z","updated_at":"2025-02-25T15:10:16.692Z","phase":"Phase 1","brief_title":"Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors","source_id_and_acronym":"NCT02496208","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 152","initiation":"Initiation: 07/22/2015","start_date":" 07/22/2015","primary_txt":" Primary completion: 09/30/2026","primary_completion_date":" 09/30/2026","study_txt":" Completion: 09/30/2026","study_completion_date":" 09/30/2026","last_update_posted":"2025-02-13"},{"id":"12b710b2-1109-43fb-8b55-f68f0578591b","acronym":"FIT-001","url":"https://clinicaltrials.gov/study/NCT06026410","created_at":"2023-09-07T16:09:33.674Z","updated_at":"2025-02-25T14:18:15.893Z","phase":"Phase 1","brief_title":"KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors","source_id_and_acronym":"NCT06026410 - FIT-001","lead_sponsor":"Kura Oncology, Inc.","biomarkers":" KRAS • NRAS • HRAS","pipe":" | ","alterations":" KRAS mutation • HRAS mutation","tags":["KRAS • NRAS • HRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • HRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cabometyx (cabozantinib tablet) • Krazati (adagrasib) • darlifarnib (KO-2806)"],"overall_status":"Recruiting","enrollment":" Enrollment 270","initiation":"Initiation: 10/18/2023","start_date":" 10/18/2023","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 04/01/2027","study_completion_date":" 04/01/2027","last_update_posted":"2025-02-12"},{"id":"d4207de7-4d28-4ffe-a877-c2adf5f87729","acronym":"","url":"https://clinicaltrials.gov/study/NCT05904080","created_at":"2023-06-15T18:09:01.233Z","updated_at":"2025-02-25T15:28:06.715Z","phase":"Phase 2","brief_title":"Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer","source_id_and_acronym":"NCT05904080","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • ABP 206 (nivolumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 02/19/2024","start_date":" 02/19/2024","primary_txt":" Primary completion: 06/16/2028","primary_completion_date":" 06/16/2028","study_txt":" Completion: 06/16/2028","study_completion_date":" 06/16/2028","last_update_posted":"2025-02-12"},{"id":"2aac339a-fbd4-48aa-9c04-5e7a6adc7234","acronym":"NCI-MATCH","url":"https://clinicaltrials.gov/study/NCT02465060","created_at":"2021-01-17T17:15:30.769Z","updated_at":"2025-02-25T16:36:36.993Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","source_id_and_acronym":"NCT02465060 - NCI-MATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["MSI • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bendamustine • bicalutamide • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • Fakzynja (defactinib) • GSK2636771 • Zirabev (bevacizumab-bvzr) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • mesna • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Paletan (pertuzumab biosimilar) • Provenge (sipuleucel-T) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Pertuvia (pertuzumab biosimilar) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6452","initiation":"Initiation: 08/17/2015","start_date":" 08/17/2015","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"868ab017-feca-462a-908a-0cf81a5b86b7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04310007","created_at":"2021-01-18T20:53:46.863Z","updated_at":"2025-02-25T16:37:47.177Z","phase":"Phase 2","brief_title":"Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer","source_id_and_acronym":"NCT04310007","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • PD-L1 • KRAS • BRAF • ALK • ROS1","pipe":" | ","alterations":" KRAS G12C • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • ALK rearrangement • EGFR L861Q • ROS1 positive • KRAS G12 • EGFR exon 20 mutation • MET positive • EGFR negative","tags":["EGFR • PD-L1 • KRAS • BRAF • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS G12C • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • ALK rearrangement • EGFR L861Q • ROS1 positive • KRAS G12 • EGFR exon 20 mutation • MET positive • EGFR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • gemcitabine • docetaxel • Cabometyx (cabozantinib tablet) • albumin-bound paclitaxel • Cyramza (ramucirumab) • Cometriq (cabozantinib capsule) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar) • lexatumumab (ETR2-ST01) • liposomal gemcitabine (FF-10832)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 117","initiation":"Initiation: 07/13/2020","start_date":" 07/13/2020","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-02-06"},{"id":"a58385e3-f746-48dd-bf8f-10d8e83d28bc","acronym":"","url":"https://clinicaltrials.gov/study/NCT01708954","created_at":"2021-01-18T07:26:37.698Z","updated_at":"2025-02-25T16:36:12.668Z","phase":"Phase 2","brief_title":"Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer","source_id_and_acronym":"NCT01708954","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • KRAS • BRAF • RET","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • BRAF mutation • EGFR L858R • EGFR exon 19 deletion • RET mutation • RET rearrangement • EGFR L858R + EGFR exon 19 deletion","tags":["HER-2 • KRAS • BRAF • RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • BRAF mutation • EGFR L858R • EGFR exon 19 deletion • RET mutation • RET rearrangement • EGFR L858R + EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 125","initiation":"Initiation: 02/13/2013","start_date":" 02/13/2013","primary_txt":" Primary completion: 08/14/2015","primary_completion_date":" 08/14/2015","study_txt":" Completion: 03/07/2025","study_completion_date":" 03/07/2025","last_update_posted":"2025-02-06"},{"id":"b94d473a-a828-47ba-9b4c-363678434e70","acronym":"PDIGREE","url":"https://clinicaltrials.gov/study/NCT03793166","created_at":"2021-01-18T18:45:15.236Z","updated_at":"2025-02-25T16:44:31.244Z","phase":"Phase 3","brief_title":"Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study","source_id_and_acronym":"NCT03793166 - PDIGREE","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1175","initiation":"Initiation: 06/07/2019","start_date":" 06/07/2019","primary_txt":" Primary completion: 09/15/2025","primary_completion_date":" 09/15/2025","study_txt":" Completion: 09/15/2025","study_completion_date":" 09/15/2025","last_update_posted":"2025-02-06"},{"id":"6b19c0a6-ae66-4201-9c5b-978c28f8c121","acronym":"","url":"https://clinicaltrials.gov/study/NCT04514484","created_at":"2021-01-18T21:38:07.896Z","updated_at":"2025-02-25T16:45:04.992Z","phase":"Phase 1","brief_title":"Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV","source_id_and_acronym":"NCT04514484","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD276 • VTCN1 • CD4 • HHLA2","pipe":"","alterations":" ","tags":["CD276 • VTCN1 • CD4 • HHLA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 11/22/2021","start_date":" 11/22/2021","primary_txt":" Primary completion: 11/02/2025","primary_completion_date":" 11/02/2025","study_txt":" Completion: 11/02/2025","study_completion_date":" 11/02/2025","last_update_posted":"2025-02-05"},{"id":"92ca3540-a2c4-478b-a664-5f10aca9b49c","acronym":"MAIN-CAV","url":"https://clinicaltrials.gov/study/NCT05092958","created_at":"2021-10-26T21:53:06.212Z","updated_at":"2025-02-25T16:53:55.916Z","phase":"Phase 3","brief_title":"Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study","source_id_and_acronym":"NCT05092958 - MAIN-CAV","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IFNA1","pipe":"","alterations":" ","tags":["IFNA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 654","initiation":"Initiation: 06/03/2022","start_date":" 06/03/2022","primary_txt":" Primary completion: 12/10/2025","primary_completion_date":" 12/10/2025","study_txt":" Completion: 12/10/2025","study_completion_date":" 12/10/2025","last_update_posted":"2025-02-04"},{"id":"fc12ec5e-bd90-482d-9d25-a68cd6f10bca","acronym":"LIBRETTO-531","url":"https://clinicaltrials.gov/study/NCT04211337","created_at":"2021-01-18T20:30:33.890Z","updated_at":"2025-02-25T16:52:48.085Z","phase":"Phase 3","brief_title":"A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer","source_id_and_acronym":"NCT04211337 - LIBRETTO-531","lead_sponsor":"Loxo Oncology, Inc.","biomarkers":" RET","pipe":" | ","alterations":" RET mutation","tags":["RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cabometyx (cabozantinib tablet) • Retevmo (selpercatinib) • Caprelsa (vandetanib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 291","initiation":"Initiation: 02/11/2020","start_date":" 02/11/2020","primary_txt":" Primary completion: 05/22/2023","primary_completion_date":" 05/22/2023","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2025-02-04"},{"id":"72fa1140-099d-4afe-8888-01f1693d9f42","acronym":"","url":"https://clinicaltrials.gov/study/NCT04551430","created_at":"2021-01-18T21:45:48.590Z","updated_at":"2025-02-25T14:29:34.223Z","phase":"Phase 2","brief_title":"Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma","source_id_and_acronym":"NCT04551430","lead_sponsor":"Washington University School of Medicine","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 105","initiation":"Initiation: 01/05/2021","start_date":" 01/05/2021","primary_txt":" Primary completion: 06/26/2024","primary_completion_date":" 06/26/2024","study_txt":" Completion: 06/01/2030","study_completion_date":" 06/01/2030","last_update_posted":"2025-02-03"},{"id":"990745fb-539d-4f49-af75-2c60fb48d354","acronym":"LUNG-IST-127","url":"https://clinicaltrials.gov/study/NCT05613413","created_at":"2022-11-14T15:57:09.508Z","updated_at":"2025-02-25T17:02:15.185Z","phase":"Phase 2","brief_title":"A Pilot Phase II Study of Maintenance Cabozantinib Plus Pembrolizumab for Patients with Metastatic Squamous Non-Small Cell Lung Cancer (sqNSCLC)","source_id_and_acronym":"NCT05613413 - LUNG-IST-127","lead_sponsor":"University of Illinois at Chicago","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Cabometyx (cabozantinib tablet)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 12/28/2022","start_date":" 12/28/2022","primary_txt":" Primary completion: 09/01/2028","primary_completion_date":" 09/01/2028","study_txt":" Completion: 09/01/2028","study_completion_date":" 09/01/2028","last_update_posted":"2025-02-03"},{"id":"727643b8-a896-41d1-b305-2893939501cb","acronym":"","url":"https://clinicaltrials.gov/study/NCT04631744","created_at":"2021-01-19T20:36:38.297Z","updated_at":"2025-02-25T17:30:30.138Z","phase":"Phase 2","brief_title":"Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)","source_id_and_acronym":"NCT04631744","lead_sponsor":"Weill Medical College of Cornell University","biomarkers":" FLT3 • NTRK2 • AXL • KDR • FLT1 • FLT4","pipe":"","alterations":" ","tags":["FLT3 • NTRK2 • AXL • KDR • FLT1 • FLT4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cabometyx (cabozantinib tablet)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 03/03/2021","start_date":" 03/03/2021","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2025-01-31"},{"id":"1eead00e-edcb-481b-9a08-390ddb32d124","acronym":"CAMILLA","url":"https://clinicaltrials.gov/study/NCT03539822","created_at":"2021-10-27T20:54:20.716Z","updated_at":"2025-02-25T15:07:39.664Z","phase":"Phase 1/2","brief_title":"Cabozantinib Plus Durvalumab with or Without Tremelimumab in Patients with Gastroesophageal Cancer and Other Gastrointestinal Malignancies","source_id_and_acronym":"NCT03539822 - CAMILLA","lead_sponsor":"Anwaar Saeed","biomarkers":" MSI","pipe":" | ","alterations":" RAS wild-type","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Cabometyx (cabozantinib tablet) • Imjudo (tremelimumab-actl)"],"overall_status":"Recruiting","enrollment":" Enrollment 117","initiation":"Initiation: 10/22/2018","start_date":" 10/22/2018","primary_txt":" Primary completion: 01/31/2027","primary_completion_date":" 01/31/2027","study_txt":" Completion: 01/31/2028","study_completion_date":" 01/31/2028","last_update_posted":"2025-01-14"},{"id":"e31b42b2-f7e8-44ab-9de8-d823f2ad231d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04091750","created_at":"2025-02-26T07:16:40.448Z","updated_at":"2025-02-26T07:16:40.448Z","phase":"Phase 2","brief_title":"Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma","source_id_and_acronym":"NCT04091750","lead_sponsor":"Georgetown University","biomarkers":" TMB • CD31 • PECAM1","pipe":"","alterations":" ","tags":["TMB • CD31 • PECAM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 14","initiation":"Initiation: 03/02/2020","start_date":" 03/02/2020","primary_txt":" Primary completion: 08/08/2023","primary_completion_date":" 08/08/2023","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-11-27"},{"id":"998f99f7-2396-457e-a574-24c4813e4cc7","acronym":"CANOPY","url":"https://clinicaltrials.gov/study/NCT05502315","created_at":"2022-08-16T11:56:11.665Z","updated_at":"2025-02-25T14:17:12.304Z","phase":"Phase 2","brief_title":"Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer","source_id_and_acronym":"NCT05502315 - CANOPY","lead_sponsor":"Rana McKay, MD","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Cabometyx (cabozantinib tablet)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 02/02/2023","start_date":" 02/02/2023","primary_txt":" Primary completion: 04/12/2026","primary_completion_date":" 04/12/2026","study_txt":" Completion: 04/12/2027","study_completion_date":" 04/12/2027","last_update_posted":"2024-07-18"},{"id":"1e4d0282-247c-4733-a3da-73f5c432fdbc","acronym":"","url":"https://clinicaltrials.gov/study/NCT03957551","created_at":"2021-01-18T19:28:34.360Z","updated_at":"2024-07-02T16:34:25.790Z","phase":"Phase 1/2","brief_title":"Cabozantinib and Pembrolizumab for Advanced Metastatic Melanoma","source_id_and_acronym":"NCT03957551","lead_sponsor":"Yousef Zakharia","biomarkers":" PD-L1 • BRAF","pipe":"","alterations":" ","tags":["PD-L1 • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)"],"overall_status":"Recruiting","enrollment":" Enrollment 62","initiation":"Initiation: 08/27/2019","start_date":" 08/27/2019","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-06-14"},{"id":"8a7d8fd2-e417-4b0d-b5df-23b7ec688150","acronym":"","url":"https://clinicaltrials.gov/study/NCT04412629","created_at":"2021-01-18T21:16:23.425Z","updated_at":"2024-07-02T16:34:25.683Z","phase":"Phase 2","brief_title":"Cabozantinib in High Grade Neuroendocrine Neoplasms","source_id_and_acronym":"NCT04412629","lead_sponsor":"Washington University School of Medicine","biomarkers":" SYP","pipe":"","alterations":" ","tags":["SYP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • Cabometyx (cabozantinib tablet)"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 11/24/2020","start_date":" 11/24/2020","primary_txt":" Primary completion: 07/31/2025","primary_completion_date":" 07/31/2025","study_txt":" Completion: 03/31/2026","study_completion_date":" 03/31/2026","last_update_posted":"2024-06-14"},{"id":"ad64e5d0-95d3-4f41-a430-f89469610dd7","acronym":"","url":"https://clinicaltrials.gov/study/NCT03914300","created_at":"2023-12-06T21:16:15.541Z","updated_at":"2024-07-02T16:34:26.125Z","phase":"Phase 2","brief_title":"Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer","source_id_and_acronym":"NCT03914300","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • PD-1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • ABP 206 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 02/10/2020","start_date":" 02/10/2020","primary_txt":" Primary completion: 10/31/2024","primary_completion_date":" 10/31/2024","study_txt":" Completion: 10/31/2024","study_completion_date":" 10/31/2024","last_update_posted":"2024-06-14"},{"id":"aff3e72a-a029-43e5-b059-ba3db87de101","acronym":"","url":"https://clinicaltrials.gov/study/NCT05127824","created_at":"2021-11-19T12:53:43.443Z","updated_at":"2024-07-02T16:34:26.105Z","phase":"Phase 2","brief_title":"Autologous Dendritic Cell Vaccine in Kidney Cancer","source_id_and_acronym":"NCT05127824","lead_sponsor":"Jodi Maranchie","biomarkers":" ER • CD8 • PD-1 • IFNG • LAG3 • TIGIT • LAMP3 • GZMB • BTLA • CD31 • NRP1 • PECAM1 • ANXA5","pipe":"","alterations":" ","tags":["ER • CD8 • PD-1 • IFNG • LAG3 • TIGIT • LAMP3 • GZMB • BTLA • CD31 • NRP1 • PECAM1 • ANXA5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • aDC1 vaccine"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 07/06/2023","start_date":" 07/06/2023","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-06-14"},{"id":"eb48e074-c9c1-4740-b335-db17f9ac4451","acronym":"PAPMET","url":"https://clinicaltrials.gov/study/NCT02761057","created_at":"2024-02-04T01:56:06.891Z","updated_at":"2024-07-02T16:34:26.084Z","phase":"Phase 2","brief_title":"Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed","source_id_and_acronym":"NCT02761057 - PAPMET","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MET","pipe":" | ","alterations":" MET mutation • MET expression","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET mutation • MET expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • sunitinib • Cabometyx (cabozantinib tablet) • Orpathys (savolitinib) • Cometriq (cabozantinib capsule)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 152","initiation":"Initiation: 07/25/2016","start_date":" 07/25/2016","primary_txt":" Primary completion: 10/02/2023","primary_completion_date":" 10/02/2023","study_txt":" Completion: 12/12/2024","study_completion_date":" 12/12/2024","last_update_posted":"2024-06-14"},{"id":"4e73113a-e7c6-4265-b9e7-7ae0a32bcfd0","acronym":"","url":"https://clinicaltrials.gov/study/NCT06006013","created_at":"2023-08-23T16:10:49.453Z","updated_at":"2024-07-02T16:34:36.827Z","phase":"Phase 2","brief_title":"Cabozantinib in Combination With Atezolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer","source_id_and_acronym":"NCT06006013","lead_sponsor":"Emory University","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 21","initiation":"Initiation: 03/05/2024","start_date":" 03/05/2024","primary_txt":" Primary completion: 12/16/2025","primary_completion_date":" 12/16/2025","study_txt":" Completion: 12/16/2025","study_completion_date":" 12/16/2025","last_update_posted":"2024-06-10"}]